Cradel Pharma :To enter the capsule manufacturing segment
It was way back in 1990 when M. K. Bakshi thought of setting up a pharmaceutical company after gaining considerable expertise in the business of chemicals and pharmaceuticals.
His idea translated into a reality and saw the ray of light in 1991. A new company, Cradel Pharmaceutical Private Limited was incorporated on February 21, 1991 and the construction of a state-of-the-art manufacturing facility at Pailan, on Diamond Harbour Road, near IIMC campus at Joka started immediately. The construction work was completed in October 1991 and commercial production started soon after in November.
Since then the Company has not looked back. It entered into a strategic agreement with Merck Limited – India (earstwhile E-Merck India Ltd.) to produce the Vitamin-B complex Syrup, namely ‘Polybion’ of the Company. Today, the company produces 15 million bottles annually of this product, adding quite a few new items to its basket. The company deploys highly professional thoroughbed people for its manufacturing activities as well as in Quality Control and Assurance Department.
“Today, we have completed almost 17 years of successful association with a MNC like Merck Limited and plan to carry it forward”, said M. K. Bakshi, Managing Director, Cradel Pharmaceuticals Limited.
Bakshi said ” We have been able to take this relationship forward in the last 17 years because of the confidence reposed on us by Merck. Cradel too has reciprocated by producing Merck’s products maintaining the highest levels of quality standards”.
In the year 1996 the company had approached the State’s Drug Control to obtain the good manufacturing practice (GMP) certification and after stringent checking and recheking of the manufacturing facility, the stringently maintained quality control measures and the over all facilities at factory, the inspection team of the state drug control Directorate awarded the company the cGMP certification. In the year 1998, the company also accolades with the WHO-GMP. Certification for its overall quality consciousness and an all round merit in the production and documentation facilities followed on a regular basis.
“Today it is rated as one of the best manufacturing facilities in the state”, admitted a senior official of the State’s Directorate of Drug Control.
Bakshi said: “Now, when the Bengal pharma companies are exploring the possibilities of entering into contract / co-manufacturing alliance with large pharma companies, Cradel has done this almost two decades back and still doing it successfully. The Bengal pharma companies can take a lesson from such a business alliance.”
“The vision and the untiring efforts of our Managing Director and the Cradel team have made this possible” said a senior official of Cradel Pharmaceuticals.
In this changed global environment, the organisation’s efforts are focused to achieve more meaningful relationship with the work force, the ultimate goal being to attain nearly zero-defect production infrastructure, backed by an efficient quality assurance unit.
Bakshi said ” We were first in the state to comply with the revised Schedule-M norms”. Today Cradel manufacturing facility conforms to the international standard of production. “We had to shut down our manufacturing process for six months to completely renovate our manufacturing facility”.
Commenting on the future plan of the company, Bakshi said “We intend to rope in other leading pharma companies to produce their products at our facility. We planned to effectively use our idle capacity”.
Besides, the company also has plans to increase its own product basket. “At present we are producing and marketing our existing product basket extensively in almost all the districts of Bengal. These products, which constitute vitamins, cough syrups and liver tonics, are well accepted in West Bengal. We will venture into new territories in the Eastern part of the country soon”, he added.
“We also have plans to foray into the capsule manufacturing segment shortly,” he said. The Company’s turnover stood at Rs. 220 million in the last fiscal.